No single diet pill works well for everyone, but several prescription medications have strong clinical evidence behind them. The most effective options right now are injectable GLP-1 receptor agonists like semaglutide and tirzepatide, which produce average weight losses in the range of 15 to 20 percent of body weight in trials. Older prescription pills like phentermine-topiramate and naltrexone-bupropion also help, though with more modest results. Over-the-counter “fat burner” supplements, despite their popularity, lack reliable evidence of effectiveness and carry real safety risks. The honest answer to “what is a good diet pill” depends on your medical history, your budget, and whether you have access to a prescriber willing to work with you long-term.
The Prescription Options That Have the Strongest Evidence
The FDA has approved a handful of medications specifically for weight management, and they work through different pathways. Understanding the basic categories helps you have an informed conversation with a doctor rather than guessing from advertisements.
GLP-1 receptor agonists are the headliners. Semaglutide (branded as Wegovy for weight loss, Ozempic for diabetes) and tirzepatide (Zepbound for weight loss, Mounjaro for diabetes) are injectable drugs that mimic gut hormones involved in appetite regulation and blood sugar control. Tirzepatide activates two receptors instead of one, and in head-to-head comparisons tends to produce slightly more weight loss. Large cardiovascular outcomes trials have shown that several GLP-1 drugs also reduce heart attacks, strokes, and cardiovascular death, which matters because obesity raises the risk of all of those things.1PubMed. Cardiovascular Risk Reduction With GLP-1 RA Drugs
Phentermine-topiramate (Qsymia) combines a stimulant appetite suppressant with an anti-seizure drug that also blunts hunger. It typically produces weight loss in the range of 7 to 10 percent of body weight over a year, which is less dramatic than the GLP-1 drugs but still clinically meaningful. The trade-off is a slight increase in heart rate, so people with uncontrolled heart conditions are usually steered away from it.2PubMed. A review of the metabolic effects of controlled-release Phentermine/Topiramate
Naltrexone-bupropion (Contrave) pairs an opioid-blocker with an antidepressant. Brain imaging research shows the combination works by dampening the hypothalamus’s response to food cues while boosting activity in brain regions tied to self-control and internal awareness.3International Journal of Obesity. Effect of combined naltrexone and bupropion therapy on the brain’s reactivity to food cues Average weight loss runs around 5 to 8 percent of body weight. It can be a reasonable option for people who also struggle with cravings or emotional eating, though it carries warnings about suicidal thoughts and should not be used alongside opioid painkillers.
Orlistat (Xenical by prescription, Alli over the counter at half dose) is the oldest remaining option. It blocks roughly a third of the fat you eat from being absorbed. The weight loss it produces is modest, and the side effects are memorably unpleasant: oily stools, anal leakage, and urgent bowel movements, especially after high-fat meals.4PubMed Central. Taking Orlistat: Predicting Weight Loss over 6 Months Some researchers have actually argued that these side effects act as a behavioral nudge, training people to eat less fat simply to avoid the consequences. It is the least effective of the approved options but also the only one available without a full prescription (in its lower-dose form).
What About Metformin for Weight Loss
Metformin is not FDA-approved for weight loss, but doctors sometimes prescribe it off-label, especially for people with insulin resistance or prediabetes. A randomized trial in non-diabetic obese women found that metformin combined with a low-calorie diet reduced BMI by about 4.5 percent over the study period, compared with about 2.6 percent for diet alone.5European Journal of Endocrinology. Metformin induces weight loss associated with gut microbiota alteration in non-diabetic obese women That extra couple of percentage points is real but underwhelming next to GLP-1 drugs. Metformin seems to work best in people with severe insulin resistance; those who are insulin-sensitive tend to lose less weight on it.6PubMed. Effectiveness of metformin on weight loss in non-diabetic individuals with obesity It is cheap, widely available, and has decades of safety data behind it, which makes it a practical if unspectacular choice for the right patient.
Why Over-the-Counter Diet Supplements Are Risky
Despite thin evidence that they actually work, weight-loss supplements are widely used. Global surveys suggest roughly 9 percent of adolescents have tried them at some point in their lives, and usage rates in the United States and Australia run above the global average.7PubMed Central. The regulation on the use of supplements for weight control: Case studies from Australia, the United States of America, and the United Kingdom The problem is not just that they do not produce meaningful weight loss. The problem is that they can cause serious harm.
Dietary supplements in the United States are regulated more like food than like drugs, which means they can reach store shelves without proving safety or effectiveness. Liver damage is the risk that shows up most often in the medical literature. Products like Hydroxycut have been repeatedly linked to liver injury, ranging from mild inflammation to outright liver failure requiring a transplant.8PubMed Central. Hydroxycut hepatotoxicity: a case series and review of liver toxicity from herbal weight loss supplements Among the non-bodybuilding herbal supplements implicated in liver damage, weight-loss products are one of the most common categories.9PubMed Central. Liver Injury from Herbal, Dietary, and Weight Loss Supplements: a Review
Some of the individual ingredients in these products have known toxic potential. Green tea extract, which sounds harmless, contains a compound called EGCG that at high doses can destroy liver cells. Usnic acid, found in some “fat burner” blends, has caused fulminant liver failure. One case report describes a young, otherwise healthy woman who needed an emergency liver transplant after taking a supplement containing usnic acid, green tea extract, and guggul tree extract.10PubMed Central. Acute liver failure caused by ‘fat burners’ and dietary supplements: a case report and literature review People tend to assume herbal means safe, but “natural” ingredients processed into concentrated pill form behave like drugs in the body, just without the safety testing that actual drugs go through.
Side Effects of Prescription Weight-Loss Medications
Prescription options are tested much more rigorously, but they are not side-effect-free. Nausea, vomiting, diarrhea, and constipation are the most common complaints with GLP-1 drugs and usually show up during the dose-escalation phase, when the body is adjusting. For most people, these symptoms fade over the first few weeks at a stable dose.11PubMed. Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists: A State-of-the-Art Narrative Review
More concerning but less common are risks that have emerged as millions of people have started using these drugs. A large study comparing GLP-1 agonists to naltrexone-bupropion found that GLP-1 users had a roughly ninefold higher risk of pancreatitis and a roughly fourfold higher risk of bowel obstruction.12JAMA. Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss These are still rare events in absolute terms, but they matter if you have a personal history of pancreatic problems or gastrointestinal conditions. Gallbladder problems, gastroparesis (severely delayed stomach emptying), and rare associations with a type of thyroid cancer have also been flagged through post-marketing surveillance, though the thyroid cancer link comes mostly from animal studies and isolated case reports.11PubMed. Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists: A State-of-the-Art Narrative Review
The Muscle Loss Problem
One issue that gets too little attention in the hype around GLP-1 drugs is what happens to muscle. When you lose a large amount of weight quickly, you do not lose only fat. Trial data suggest that people on these medications for about 68 to 72 weeks lost 10 percent or more of their skeletal muscle mass, roughly equivalent to 20 years of age-related muscle decline compressed into a year and a half.13PubMed Central. Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesity For a 35-year-old, that might not cause immediate problems. For someone in their sixties, that amount of muscle loss can mean the difference between living independently and struggling with falls and frailty.
This is one of the strongest arguments for combining weight-loss medication with resistance exercise rather than relying on the drug alone. Lifting weights or doing other strength-based activity signals the body to preserve muscle even while overall weight is dropping. If you are considering any medication that produces rapid, substantial weight loss, discussing a concurrent exercise plan with your provider is worth the conversation.
What Happens When You Stop Taking the Medication
This is the question people often do not ask until they are already on a drug. The evidence here is sobering. In the STEP 1 trial extension, people who stopped semaglutide after about a year of treatment regained roughly two-thirds of the weight they had lost within the following year. They still ended up about 5.6 percent lighter than their starting weight, but the trajectory was clearly heading back toward baseline.14PubMed Central. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
A 2025 systematic review looking across multiple medications found that the average rate of weight regain after stopping was about 0.4 kilograms per month, and all the improvements in blood pressure, cholesterol, and blood sugar that came with the weight loss were projected to reverse within roughly a year and a half. The review also found that weight regain after stopping medication was faster than weight regain after completing a structured behavioral program alone, which suggests the drugs may suppress weight without fully retraining the body’s set-point mechanisms.15BMJ. Weight regain after cessation of medication for weight management: systematic review and meta-analysis
The practical takeaway is that for many people, these medications may need to be taken indefinitely to maintain their effects, much like blood pressure or cholesterol drugs. That changes the cost calculus dramatically and is something to think about before starting.
How Exercise Changes the Long-Term Picture
One of the more encouraging findings in recent research is that combining a GLP-1 drug with structured exercise produces benefits that outlast treatment better than the drug alone. A randomized trial tested liraglutide (an older GLP-1 drug) with and without an exercise program. One year after both treatments ended, the group that had done exercise plus liraglutide had kept off significantly more weight and more body fat than those who had taken liraglutide alone. People in the combination group were over four times more likely to have maintained at least 10 percent total body weight loss compared to the liraglutide-only group.16PubMed Central. Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment
This finding matters because it suggests exercise does something the drugs cannot: it changes the body’s metabolic and behavioral baseline in a way that persists after the pill or injection stops. Given the muscle loss concern mentioned earlier, exercise appears to solve two problems at once, preserving lean mass while extending the durability of weight loss.
Who Can Actually Afford and Access These Drugs
The best medication in the world does not help if you cannot get it. Access to newer weight-loss drugs is severely limited for a large portion of the population.17PubMed Central. Addressing insurance-related barriers to novel antiobesity medications: Lessons to be learned from bariatric surgery Many insurance plans still classify obesity medications as “lifestyle” products and refuse to cover them. Medicare, which covers tens of millions of older Americans, has historically excluded weight-loss drugs from its formulary, though legislative efforts to change that are ongoing.
The cost barriers do not fall evenly. Among American adults who would medically qualify for semaglutide, about a third had low family income, roughly 12 percent were uninsured, and about 13 percent lacked a usual source of healthcare. These barriers were significantly more pronounced for Black and Hispanic individuals compared with White individuals across every measure studied.18PubMed Central. Racial and Ethnic Disparities in Financial Barriers Among Overweight and Obese Adults Eligible for Semaglutide in the United States Without insurance coverage, a month’s supply of semaglutide or tirzepatide can cost over $1,000 at list price, which means these breakthrough medications are functionally unavailable to the people who often need them most.
The clinical trial populations do not reflect the real-world population either. A systematic review of obesity drug trials found that white participants made up about 79 percent of enrollees in GLP-1 trials, and the vast majority of trial sites were in high-income countries.19BMJ. Representation of racialised and ethnically diverse populations in multicentre randomised controlled trials of GLP-1 medicines for obesity That gap matters because obesity-related metabolic risk varies across racial and ethnic groups in ways that could affect treatment response. We are applying these drugs broadly based on trials that were tested narrowly.
A Messy Track Record Worth Knowing
The history of diet pills is littered with drugs that were once considered “good” before they were pulled from the market for causing serious harm. Aminorex, popular in the 1960s, caused a surge of fatal pulmonary hypertension. The fenfluramine drugs, including the infamous “fen-phen” combination, were withdrawn worldwide in 1997 after causing heart valve damage and pulmonary hypertension.20PubMed. Safety of drug therapies used for weight loss and treatment of obesity Phenylpropanolamine, once in many over-the-counter cold and diet remedies, was pulled in 2000 for causing hemorrhagic stroke. Sibutramine (Meridia) was removed after reports of serious cardiovascular events, including deaths.21PubMed Central. Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review A systematic review counted 25 anti-obesity products withdrawn from at least one country, with heart damage and psychiatric effects as the two leading reasons.
This history does not mean today’s approved medications will follow the same path. The current generation has been through much larger and more rigorous trials. But it does explain why regulators and doctors approach new weight-loss drugs with healthy skepticism, and why you should too. Any pill that meaningfully changes your metabolism is doing something powerful to your body. Powerful interventions come with risks, and some of those risks only become clear after millions of people have used a drug for years.
What Is Coming Next
The pipeline of new obesity drugs is the most active it has ever been. The most talked-about candidate is retatrutide, which activates three receptors instead of the one or two targeted by current drugs. In a phase 2 trial, people on the highest dose of retatrutide lost about 24 percent of their body weight over 48 weeks, substantially more than what semaglutide achieves at its approved dose.22PubMed. Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial A meta-analysis of available trial data confirmed significant reductions in weight, waist circumference, fasting blood sugar, and blood pressure across multiple doses.23PubMed Central. Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment In people with type 2 diabetes, the drug showed both strong blood sugar control and weight reductions of up to about 17 percent.24The Lancet. Retatrutide, a triple GIP, GLP-1 and glucagon receptor agonist, in people with type 2 diabetes
Other compounds are also in development, including bimagrumab, which works through an entirely different pathway by targeting receptors involved in muscle and fat regulation.25PubMed Central. Next Generation Antiobesity Medications: Setmelanotide, Semaglutide, Tirzepatide and Bimagrumab If bimagrumab or something like it pans out, it could address the muscle-loss problem by helping the body shed fat while preserving or even building muscle. These are still in earlier stages of testing, so it will be years before they are available, but the direction of research is clearly toward drugs that produce bigger weight losses with fewer metabolic trade-offs.
When Weight-Loss Medication Intersects With Eating Disorders
One angle that rarely comes up in consumer-facing discussions is the relationship between eating disorder symptoms and the desire for weight-loss drugs. Research has found that women with higher levels of eating disorder-related psychological distress at one point in time were significantly more likely to be using weight-loss medications or supplements six months later. For every one-point increase in eating disorder symptom scores, the odds of using a GLP-1 medication doubled.26PubMed Central. Eating disorder psychopathology relates to weight loss medication and supplement use 6 months later in women
This does not mean everyone who takes a weight-loss drug has an eating disorder. But it does mean the population of people seeking these medications includes a meaningful subset who are driven by disordered thinking about food and body image rather than by medical need. For those individuals, a pill that dramatically suppresses appetite could reinforce harmful patterns. If you recognize obsessive thoughts about food, cycles of restriction and bingeing, or intense distress about body shape that interferes with daily life, bringing those concerns to a provider before starting medication is important. A good prescriber will screen for this; a prescription mill dispensing weight-loss drugs through a five-minute telehealth visit probably will not.